<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009722</url>
  </required_header>
  <id_info>
    <org_study_id>13-008490</org_study_id>
    <nct_id>NCT02009722</nct_id>
  </id_info>
  <brief_title>Intrathecal Opioids for Pain Control After Cesarean Delivery: Determining the Optimal Dose</brief_title>
  <official_title>Intrathecal Opioids for Pain Control After Cesarean Delivery: Determining the Optimal Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Both hydromorphone and morphine are administered as part of spinal anesthesia to help improve
      pain control after cesarean delivery. In this study, the investigators are going to determine
      the doses of each of those medicines that provides optimal pain control to women undergoing
      cesarean delivery while limiting side effects related to those medicines. The investigators
      hypothesize that the doses of hydromorphone and morphine that provide optimal pain control
      without significant side effects will be 100 micrograms and 150 micrograms, respectively. The
      investigators further hypothesize that at each respective optimal dose, side effects will be
      less in the hydromorphone group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal anesthesia is the most common anesthetic technique used for Cesarean delivery in the
      United States and across the world. Intrathecal opioids are administered along with a local
      anesthetic during spinal anesthesia for Cesarean delivery to provide postoperative analgesia.
      The effectiveness of intrathecal morphine for post-Cesarean pain control is well established,
      but the effectiveness of intrathecal hydromorphone in this patient population is limited to
      case reports and small retrospective studies. No prospective studies have been conducted to
      establish the effectiveness of intrathecal hydromorphone for post-Cesarean pain.

      Hydromorphone has been studied extensively as a substitute for intrathecal morphine in
      patients with chronic noncancer pain. In fact, a recent consensus article placed
      hydromorphone as a first line therapy along with morphine for intrathecal pain management.
      Its ability to treat post-Cesarean pain when administered in the epidural space has been
      known for quite some time, but its effects in the intrathecal space are less established. In
      patients undergoing Cesarean delivery, intrathecal doses of 40 to 100 micrograms have been
      reported to provide good pain scores postoperatively with only minimal side effects. Doses of
      up to 300 micrograms have been used, leading to excellent pain control without out
      respiratory depression, but with significant pruritus and nausea.

      Although reducing pain, intrathecal opioids are associated with side effects including
      pruritus, nausea, and respiratory depression. A meta-analysis reviewing twenty-eight studies
      which investigated intrathecal morphine versus placebo demonstrated moderate increases in the
      incidences of pruritus, nausea and vomiting. In fact the incidence of nausea with IT morphine
      has been reported to be 33%. While hydromorphone is similar chemically to morphine, it is
      metabolized differently. Differences in pharmacokinetics may allow for differences in side
      effect profiles. Hydromorphone is more lipid soluble than morphine. This decreases its spread
      within the intrathecal space and enhances its penetration into the dorsal horn of the spinal
      cord where interactions with opioid receptors occur. Some studies have found that
      hydromorphone causes less nausea and pruritus than morphine, while others have not. Although
      opioid-induced respiratory depression is a rare event, studies evaluating intrathecal
      hydromorphone for post-Cesarean delivery pain have not reported any cases of respiratory
      depression.

      The optimal dose of intrathecal morphine for analgesia following Cesarean delivery is still
      debated and the efficacy of intrathecal hydromorphone has not been studied extensively in
      this patient population. The investigators aim to identify the dose of each medication that
      provides good pain relief without causing significant side effects. The investigators will
      then perform a comparative analysis of each drug at their optimal dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose of IT Morphine and IT Hydromorphone for Adequate Analgesia (Pain Score Less Than or Equal to 3) in 90% of Patients</measure>
    <time_frame>12 hours after administration of spinal anesthesia</time_frame>
    <description>Each patient will be interviewed by a member of the study team 12 hours after receiving their spinal anesthetic (which will include either hydromorphone or morphine). Patients will be asked to rate their current level of pain on a scale of 0 (no pain) to 10 (worst pain imaginable). A pain score &lt;4 will be considered a success. The up-down sequential allocation method will be used to determine the dose (mcg) of IT hydromorphone and IT morphine for subsequent patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side Effects: Pruritus</measure>
    <time_frame>6 hours after spinal administration</time_frame>
    <description>Patients will be evaluated by a member of the study team at 6 hours after spinal administration. The number of patients with moderate or severe pruritus will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects: Nausea</measure>
    <time_frame>6 hours after spinal</time_frame>
    <description>Patients will be evaluated by a member of the study team at 6 hours after spinal administration. Patients with moderate or severe nausea will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects: Sedation</measure>
    <time_frame>6, 12, and 24 hours after spinal administration</time_frame>
    <description>Patients will be evaluated by a member of the study team at 6, 12, and 24 hours after spinal administration. The presence of sedation will be graded by the Richmond Agitation Sedation Scale. Patients with a score of (-)2 or lower on the Richmond were classified as being positive for sedation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus</measure>
    <time_frame>12 hours after spinal</time_frame>
    <description>Patients will be evaluated by a member of the study team at 12 hours after spinal administration. The number of patients with moderate or severe pruritus will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus</measure>
    <time_frame>24 hours after spinal</time_frame>
    <description>Patients will be evaluated by a member of the study team at 24 hours after spinal administration. The number of patients with moderate or severe pruritus will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>12 hours after spinal</time_frame>
    <description>Patients will be evaluated by a member of the study team at 12 hours after spinal administration. The number of patients with moderate or severe nausea will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>24 hours after spinal</time_frame>
    <description>Patients will be evaluated by a member of the study team at 24 hours after spinal administration. The number of patients with moderate or severe nausea will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment for Nausea</measure>
    <time_frame>First 24 hours</time_frame>
    <description>number of patients needing medication treatment for nausea in first 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment for Pruritus</measure>
    <time_frame>First 24 hours after spinal</time_frame>
    <description>The number of patients needing medical treatment for pruritus in first 24 hours after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Analgesia, Obstetrical</condition>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>Intrathecal hydromorphone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intrathecal morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Duramorph is administered as part of spinal anesthesia for post-operative pain relief.</description>
    <arm_group_label>Intrathecal morphine</arm_group_label>
    <other_name>Duramorph</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control</description>
    <arm_group_label>Intrathecal hydromorphone</arm_group_label>
    <other_name>Dilaudid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women presenting for elective cesarean delivery with no major co-morbidities,
             including pregnancy induced co-morbidities (e.g. pre-eclampsia)

          -  Singleton gestation at term (37-42 weeks)

          -  Desire to have a spinal anesthesia technique for cesarean delivery

        Exclusion Criteria:

          -  Current or historical evidence of clinically significant medical disease or condition

          -  Any contraindication to the administration of a spinal technique for anesthesia

          -  History of hypersensitivity or idiosyncratic reaction to opioid medications

          -  Chronic pain syndrome or current regular opioid use

          -  Evidence of anticipated fetal anomalies

          -  Allergy or intolerance to Tylenol, ketorolac, ibuprofen, or oxycodone

          -  BMI &gt; 40
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans P Sviggum, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rochester Methodist Hospital, Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Beatty NC, Arendt KW, Niesen AD, Wittwer ED, Jacob AK. Analgesia after Cesarean delivery: a retrospective comparison of intrathecal hydromorphone and morphine. J Clin Anesth. 2013 Aug;25(5):379-383. doi: 10.1016/j.jclinane.2013.01.014. Epub 2013 Aug 17.</citation>
    <PMID>23965210</PMID>
  </reference>
  <reference>
    <citation>Palmer CM, Emerson S, Volgoropolous D, Alves D. Dose-response relationship of intrathecal morphine for postcesarean analgesia. Anesthesiology. 1999 Feb;90(2):437-44. Erratum in: Anesthesiology 1999 Apr;90(4):1241.</citation>
    <PMID>9952150</PMID>
  </reference>
  <reference>
    <citation>Rauch E. Intrathecal hydromorphone for postoperative analgesia after cesarean delivery: a retrospective study. AANA J. 2012 Aug;80(4 Suppl):S25-32.</citation>
    <PMID>23248827</PMID>
  </reference>
  <reference>
    <citation>Rauch E. Intrathecal hydromorphone for cesarean delivery: in search of improved postoperative pain management: a case report. AANA J. 2011 Oct;79(5):427-32.</citation>
    <PMID>23256273</PMID>
  </reference>
  <reference>
    <citation>Terajima K, Onodera H, Kobayashi M, Yamanaka H, Ohno T, Konuma S, Ogawa R. Efficacy of intrathecal morphine for analgesia following elective cesarean section: comparison with previous delivery. J Nippon Med Sch. 2003 Aug;70(4):327-33.</citation>
    <PMID>12928713</PMID>
  </reference>
  <reference>
    <citation>Gehling M, Tryba M. Risks and side-effects of intrathecal morphine combined with spinal anaesthesia: a meta-analysis. Anaesthesia. 2009 Jun;64(6):643-51. Review.</citation>
    <PMID>19462494</PMID>
  </reference>
  <reference>
    <citation>Dougherty TB, Baysinger CL, Henenberger JC, Gooding DJ. Epidural hydromorphone with and without epinephrine for post-operative analgesia after cesarean delivery. Anesth Analg. 1989 Mar;68(3):318-22.</citation>
    <PMID>2465709</PMID>
  </reference>
  <reference>
    <citation>Pace NL, Stylianou MP. Advances in and limitations of up-and-down methodology: a pr√©cis of clinical use, study design, and dose estimation in anesthesia research. Anesthesiology. 2007 Jul;107(1):144-52. Review.</citation>
    <PMID>17585226</PMID>
  </reference>
  <reference>
    <citation>Gerancher JC, Floyd H, Eisenach J. Determination of an effective dose of intrathecal morphine for pain relief after cesarean delivery. Anesth Analg. 1999 Feb;88(2):346-51.</citation>
    <PMID>9972754</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <results_first_submitted>March 15, 2016</results_first_submitted>
  <results_first_submitted_qc>April 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2016</results_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Hans P. Sviggum, M.D.</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Cesarean Delivery</keyword>
  <keyword>Intrathecal Morphine</keyword>
  <keyword>Intrathecal Hydromorphone</keyword>
  <keyword>Obstetrical Analgesia</keyword>
  <keyword>Spinal Anesthesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intrathecal Hydromorphone</title>
          <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Hydromorphone: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control</description>
        </group>
        <group group_id="P2">
          <title>Intrathecal Morphine</title>
          <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Morphine: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Intervention</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive intervention</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intrathecal Hydromorphone</title>
          <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Hydromorphone: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control</description>
        </group>
        <group group_id="B2">
          <title>Intrathecal Morphine</title>
          <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Morphine: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="4.1"/>
                    <measurement group_id="B2" value="30.6" spread="4.3"/>
                    <measurement group_id="B3" value="30.5" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dose of IT Morphine and IT Hydromorphone for Adequate Analgesia (Pain Score Less Than or Equal to 3) in 90% of Patients</title>
        <description>Each patient will be interviewed by a member of the study team 12 hours after receiving their spinal anesthetic (which will include either hydromorphone or morphine). Patients will be asked to rate their current level of pain on a scale of 0 (no pain) to 10 (worst pain imaginable). A pain score &lt;4 will be considered a success. The up-down sequential allocation method will be used to determine the dose (mcg) of IT hydromorphone and IT morphine for subsequent patients</description>
        <time_frame>12 hours after administration of spinal anesthesia</time_frame>
        <population>The primary outcome was determining the optimal dose of IT morphine and IT hydromorphone for patients undergoing cesarean delivery. Study was designed to determine the ED90 (effective dose in 90% patients; effective dose meaning a VAS score for pain of 3 or less at 12 hours after spinal placement).</population>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Hydromorphone</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Hydromorphone: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Morphine</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Morphine: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose of IT Morphine and IT Hydromorphone for Adequate Analgesia (Pain Score Less Than or Equal to 3) in 90% of Patients</title>
          <description>Each patient will be interviewed by a member of the study team 12 hours after receiving their spinal anesthetic (which will include either hydromorphone or morphine). Patients will be asked to rate their current level of pain on a scale of 0 (no pain) to 10 (worst pain imaginable). A pain score &lt;4 will be considered a success. The up-down sequential allocation method will be used to determine the dose (mcg) of IT hydromorphone and IT morphine for subsequent patients</description>
          <population>The primary outcome was determining the optimal dose of IT morphine and IT hydromorphone for patients undergoing cesarean delivery. Study was designed to determine the ED90 (effective dose in 90% patients; effective dose meaning a VAS score for pain of 3 or less at 12 hours after spinal placement).</population>
          <units>micrograms</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects: Pruritus</title>
        <description>Patients will be evaluated by a member of the study team at 6 hours after spinal administration. The number of patients with moderate or severe pruritus will be recorded.</description>
        <time_frame>6 hours after spinal administration</time_frame>
        <population>The number of patients at the most commonly used doses of IT medication (50, 75, 100 mcg for hydromorphone) and (100, 150 mcg) for morphine were used in analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Hydromorphone</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Hydromorphone: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Morphine</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Morphine: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects: Pruritus</title>
          <description>Patients will be evaluated by a member of the study team at 6 hours after spinal administration. The number of patients with moderate or severe pruritus will be recorded.</description>
          <population>The number of patients at the most commonly used doses of IT medication (50, 75, 100 mcg for hydromorphone) and (100, 150 mcg) for morphine were used in analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects: Nausea</title>
        <description>Patients will be evaluated by a member of the study team at 6 hours after spinal administration. Patients with moderate or severe nausea will be recorded.</description>
        <time_frame>6 hours after spinal</time_frame>
        <population>The number of patients at the most commonly used doses of IT medication (50, 75, 100 mcg for hydromorphone) and (100, 150 mcg) for morphine were used in analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Hydromorphone</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Hydromorphone: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Morphine</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Morphine: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects: Nausea</title>
          <description>Patients will be evaluated by a member of the study team at 6 hours after spinal administration. Patients with moderate or severe nausea will be recorded.</description>
          <population>The number of patients at the most commonly used doses of IT medication (50, 75, 100 mcg for hydromorphone) and (100, 150 mcg) for morphine were used in analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects: Sedation</title>
        <description>Patients will be evaluated by a member of the study team at 6, 12, and 24 hours after spinal administration. The presence of sedation will be graded by the Richmond Agitation Sedation Scale. Patients with a score of (-)2 or lower on the Richmond were classified as being positive for sedation.</description>
        <time_frame>6, 12, and 24 hours after spinal administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Hydromorphone</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Hydromorphone: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Morphine</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Morphine: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects: Sedation</title>
          <description>Patients will be evaluated by a member of the study team at 6, 12, and 24 hours after spinal administration. The presence of sedation will be graded by the Richmond Agitation Sedation Scale. Patients with a score of (-)2 or lower on the Richmond were classified as being positive for sedation.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pruritus</title>
        <description>Patients will be evaluated by a member of the study team at 12 hours after spinal administration. The number of patients with moderate or severe pruritus will be recorded.</description>
        <time_frame>12 hours after spinal</time_frame>
        <population>The number of patients at the most commonly used doses of IT medication (50, 75, 100 mcg for hydromorphone) and (100, 150 mcg) for morphine were used in analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Hydromorphone</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Hydromorphone: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Morphine</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Morphine: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
        </group_list>
        <measure>
          <title>Pruritus</title>
          <description>Patients will be evaluated by a member of the study team at 12 hours after spinal administration. The number of patients with moderate or severe pruritus will be recorded.</description>
          <population>The number of patients at the most commonly used doses of IT medication (50, 75, 100 mcg for hydromorphone) and (100, 150 mcg) for morphine were used in analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pruritus</title>
        <description>Patients will be evaluated by a member of the study team at 24 hours after spinal administration. The number of patients with moderate or severe pruritus will be recorded.</description>
        <time_frame>24 hours after spinal</time_frame>
        <population>The number of patients at the most commonly used doses of IT medication (50, 75, 100 mcg for hydromorphone) and (100, 150 mcg) for morphine were used in analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Hydromorphone</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Hydromorphone: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Morphine</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Morphine: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
        </group_list>
        <measure>
          <title>Pruritus</title>
          <description>Patients will be evaluated by a member of the study team at 24 hours after spinal administration. The number of patients with moderate or severe pruritus will be recorded.</description>
          <population>The number of patients at the most commonly used doses of IT medication (50, 75, 100 mcg for hydromorphone) and (100, 150 mcg) for morphine were used in analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea</title>
        <description>Patients will be evaluated by a member of the study team at 12 hours after spinal administration. The number of patients with moderate or severe nausea will be recorded.</description>
        <time_frame>12 hours after spinal</time_frame>
        <population>The number of patients at the most commonly used doses of IT medication (50, 75, 100 mcg for hydromorphone) and (100, 150 mcg) for morphine were used in analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Hydromorphone</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Hydromorphone: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Morphine</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Morphine: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea</title>
          <description>Patients will be evaluated by a member of the study team at 12 hours after spinal administration. The number of patients with moderate or severe nausea will be recorded.</description>
          <population>The number of patients at the most commonly used doses of IT medication (50, 75, 100 mcg for hydromorphone) and (100, 150 mcg) for morphine were used in analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea</title>
        <description>Patients will be evaluated by a member of the study team at 24 hours after spinal administration. The number of patients with moderate or severe nausea will be recorded.</description>
        <time_frame>24 hours after spinal</time_frame>
        <population>The number of patients at the most commonly used doses of IT medication (50, 75, 100 mcg for hydromorphone) and (100, 150 mcg) for morphine were used in analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Hydromorphone</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Hydromorphone: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Morphine</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Morphine: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea</title>
          <description>Patients will be evaluated by a member of the study team at 24 hours after spinal administration. The number of patients with moderate or severe nausea will be recorded.</description>
          <population>The number of patients at the most commonly used doses of IT medication (50, 75, 100 mcg for hydromorphone) and (100, 150 mcg) for morphine were used in analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment for Nausea</title>
        <description>number of patients needing medication treatment for nausea in first 24 hours</description>
        <time_frame>First 24 hours</time_frame>
        <population>patients receiving most commonly used doses of IT medication (50,75,100 mcg for hydromorphone; 100, 150 mcg for morphine)</population>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Hydromorphone</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Hydromorphone: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Morphine</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Morphine: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment for Nausea</title>
          <description>number of patients needing medication treatment for nausea in first 24 hours</description>
          <population>patients receiving most commonly used doses of IT medication (50,75,100 mcg for hydromorphone; 100, 150 mcg for morphine)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment for Pruritus</title>
        <description>The number of patients needing medical treatment for pruritus in first 24 hours after surgery</description>
        <time_frame>First 24 hours after spinal</time_frame>
        <population>only patients receiving most commonly used doses of IT hydromorphone (50,75,100 mcg) and morphine (100,150 mcg)</population>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Hydromorphone</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Hydromorphone: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Morphine</title>
            <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Morphine: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment for Pruritus</title>
          <description>The number of patients needing medical treatment for pruritus in first 24 hours after surgery</description>
          <population>only patients receiving most commonly used doses of IT hydromorphone (50,75,100 mcg) and morphine (100,150 mcg)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Hydromorphone arm: 41 patients received the intervention, 40 were analyzed
Morphine arm: 43 patients were randomized to this arm, 42 received the intervention (thus the denominator for adverse events) and 40 were analyzed</desc>
      <group_list>
        <group group_id="E1">
          <title>Intrathecal Hydromorphone</title>
          <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Hydromorphone: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control</description>
        </group>
        <group group_id="E2">
          <title>Intrathecal Morphine</title>
          <description>Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
Morphine: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Pruritus</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Nausea">Moderate to Severe Nausea</sub_title>
                <description>Patients experiencing moderate to severe nausea (self-reported) within 24 hours of spinal administration</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Moderate to Severe Pruritus</sub_title>
                <description>Patients experiencing moderate to severe pruritus (self-reported) within 24 hours of spinal administration</description>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="41"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hans Sviggum</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-581-6083</phone>
      <email>sviggum.hans@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

